Buy Evista through the unique service that maximize your savings

Chain Drug Review - Lilly Ups Support for Evista

admin — Thu, 08 Jan 2009 01:26:02 +0000

INDIANAPOLIS — Eli Lilly and Co. is providing additional support for Evista, its osteoporosis preventive, by reorganizing its pharmaceutical sales force.
Evista, known generically as raloxifene hydrochloride, is marketed for the prevention of osteoporosis in postmenopausal women.
The change for the sales unit, expected to take effect next month, will increase the number of representatives detailing the drug and will enable them to call on primary care providers, rheumatologists and endocrinologists in addition to obstetricians and gynecologists.

Related Results

Evista approvalResearch on EvistaMarketing of Lilly’s Evista investigatedEvista granted priority reviewLilly’s Evista builds bone

“Our experience this year has demonstrated that physicians, armed with comprehensive data on Evista and the benefits of selective estrogens, are highly motivated to prescribe Evista to prevent osteoporosis in women,” says Alan Clark, president of U.S. operations and global marketing. “This realignment will enable us to reach more health care providers across a broader spectrum of specialty areas and ultimately more women who can benefit from Evista.”
COPYRIGHT 1998 Racher Press, Inc.
COPYRIGHT 2008 Gale, Cengage Learning

Customer Interaction Solutions - MatchLogic Enhances eVista

admin — Fri, 02 Jan 2009 11:21:02 +0000

MatchLogic, Inc. announced the Latest version of its relationship marketing application, eVista 3.0. Designed specifically for marketers, this release is intended to assist companies in better managing their customer interactions and to enable marketers to analyze customer data and create sophisticated, relevant offline and online campaigns easily.

Related Results

Evista approvalResearch on EvistaMarketing of Lilly’s Evista investigatedLilly Ups Support for EvistaEvista granted priority review

eVista 3.0’s enhancements include a browser-based interface for personalized message creation, the capability to create embedded, trackable URLs within message content, improved campaign navigation and management, content testing, message format optimization, customized e-mail campaigns with response tracking and the availability of past campaign response data as selection criteria for future campaigns.
COPYRIGHT 2001 Technology Marketing Corporation
COPYRIGHT 2008 Gale, Cengage Learning

Oncology Nursing Forum - Tablets curb breast cancer risk

admin — Thu, 01 Jan 2009 03:26:05 +0000

The (FDA) approved raloxifene hydrochloride tablets (Evista[R], Eli Lilly and Company) to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer. Evista, an oral tablet, is a selective estrogen receptor modulator and should not be used by women with a high risk for blood clots. For more information on Evista, visit www.evista.com.

Related Results

Evista approvalResearch on EvistaMarketing of Lilly’s Evista investigatedLilly Ups Support for EvistaEvista granted priority review

[ILLUSTRATION OMITTED]
COPYRIGHT 2008 Oncology Nursing Society
COPYRIGHT 2008 Gale, Cengage Learning

Chain Drug Review - Evista granted priority review

admin — Mon, 29 Dec 2008 08:01:03 +0000

Eli Lilly and Co. says that the FDA has granted a priority review for the supplemental new drug application for an osteoporosis indication for Evista. The drug has been on the market since January 1998 for use in preventing osteoporosis in postmenopausal women.

Related Results

Evista approvalResearch on EvistaMarketing of Lilly’s Evista investigatedLilly Ups Support for EvistaLilly’s Evista builds bone

Chain Drug Review - Marketing of Lilly’s Evista investigated

admin — Mon, 22 Dec 2008 09:36:03 +0000

WASHINGTON — The United States Department of Justice is investigating the way Eli Lilly and Co. is marketing its drug Evista.
The criminal inquiry, which is being conducted by the Justice Department’s Office of Consumer Litigation in cooperation with the U.S. attorney’s office in Indianapolis, is investigating whether Lilly improperly promoted Evista for the prevention of breast cancer.
While growing evidence suggests that Evista may contribute to the prevention of breast cancer (as well as potentially lowering the incidence of heart disease in some older women), the drug manufacturer is prohibited from marketing the drug as a breast cancer preventative.

Related Results

Evista approvalResearch on EvistaLilly Ups Support for EvistaEvista granted priority reviewLilly’s Evista builds bone

Evista, which is known generically as raloxifene, has been approved for the prevention and treatment of osteoporosis.
According to a published report, Lilly, which recently received a criminal subpoena for its Evista-related records, believes the federal inquiry is related to the lawsuit brought against it by Astra-Zeneca LP, charging that Lilly improperly marketed Evista. That lawsuit was settled two years ago.
COPYRIGHT 2002 Racher Press, Inc.
COPYRIGHT 2008 Gale, Cengage Learning

Medical Update - Lilly’s Evista builds bone

admin — Sat, 20 Dec 2008 02:31:03 +0000

Although hormone replacement therapy (HRT) is good for bones, recent research from the national Women’s Health Initiative study shows that HRT can increase the risk of breast cancer, heart attacks, and strokes. Dr. Jacques Rossouw, acting director of the WHI, recommends that women who are concerned about osteoporosis look into safer, effective alternatives to hormone therapy, including Evista (raloxifene hydrochloride).
Evista is neither an estrogen nor a hormone. It is a selective estrogen receptor modulator, or SERM.

Related Results

Evista approvalResearch on EvistaMarketing of Lilly’s Evista investigatedLilly Ups Support for EvistaEvista granted priority review

“Selective estrogen receptor modulators are synthetically engineered compounds that are designed to mimic estrogen effects in some tissues, like the bones and cardiovascular system,” explained Dr. John Termine, head of the Lilly Research Laboratories team on the Evista project. “At the same time, it was engineered to nonmimic estrogen in the uterus and the breast.”
Clinical trials show that the prescription drug Evista, on the market since 1997, makes bones stronger and decreases the risk of fracture in post-menopausal women. And in a recent study published in JAMA, researchers at the University of California, San Diego, found that raloxifene significantly lessened the risk of heart attacks, strokes, and other cardiovascular events among post-menopausal women.
Doctors recommend that all women take calcium, usually with vitamin D and magnesium, to help strengthen bones and prevent bone loss. Weight-bearing exercise and dietary supplements–including microcrystalline hydroxyapatite concentrate (MCHC), horsetail, and red clover–have also been noted to prevent or slow osteoporosis.
COPYRIGHT 2002 Benjamin Franklin Literary & Medical Society, Inc.
COPYRIGHT 2008 Gale, Cengage Learning

Online Canadian Pharmacy: Providing Competitive Pricing On Medications

admin — Wed, 17 Dec 2008 17:56:05 +0000

The cost of prescription drugs in different parts of the world have been rising rapidly leaving many uninsured and underinsured people with no reasonable way to incur their needed medications. With the rise of online Canadian drug pharmacy, buying prescription drugs online has become a quick and easy job. Now one can easily afford to buy prescription drugs at a faster and cheaper rate by placing an order on telephone or by regular mail. Regardless of how an order is placed, Canadian prescription drugs will be delivered quickly and safely - in about 7-10 days. One can also find, view and track order, or make changes to personal medical file at any time, from the comfort of your own home.

Canada drug pharmacy always gives secure and trustworthy environment by giving assurance of delivering top quality drugs. There are no risks of being scammed or receiving petty products. Canada is the only country that has maximum number of fully licensed online pharmacies providing discount prescription drug prices to American’s and customers all over the world. On an average patients can save a minimum of 40% and as high as 90% off their medications!

Canadian drug pharmacies provide high-quality prescription drugs online as well as over-the-counter medications at discount drug prices. Online Canada drug pharmacy offers medications made by world renowned International pharmaceutical manufactures such as Novartis, Cipla, Aventis, Dr. Reddy’s, GlaxoSmithKline, Ranbaxy, etc.

Canadian drug stores often provide medications at cheaper rates than American pharmacies. The problem with purchase of drugs in US is that the government is not regulating the price of drugs. Canadian government on the other hand regulates the prices of drugs. Heavy discounts are given on brand name and generic prescriptions drugs. Canadian drugs are of the same quality, potency, and pureness as American drugs for which many Americans are now placing their orders at online Canadian drug stores.

An intriguing fact is that most of the Americans are turning to their neighbor country Canada for an affordable prescription medication. The price of prescription medications sold in Canada is drastically less virtually without exception when compared to the United States. The volume of business catered to by Canadian discount stores is nothing but dumbfounding. Pharmacies operating at Canada are filling out prescriptions for everything from common cold to controlling blood pressure.

Canadian pharmacy drug supplies popular brand name drugs such as Celebrex, Fosamax, Lescol, Evista etc at a discounted prices. The main reason for choosing Canadian pharmacy as your alternative drug store is:

Fully licensed
Best prices on prescription drugs
Toll free phone support. Great service 24 Hours a day and 7 days a week
No currency exchanges or duty. No hidden charges or fees.
Shipping to all 50 states with a quick delivery right to your door
Fully confidential
Brand name prescription drugs and many Canadian generic drugs available

Receive brand name and generic medications from a licensed Canada drug pharmacy without sacrificing safety, quality or service. Canadian pharmacies dispense the same medications as in America, but at significant savings. Canadian drug pharmacies promise safe, effective, and affordable drug purchase experience.

New Weapons to Fight Osteoporosis

admin — Sat, 13 Dec 2008 02:51:02 +0000

The bones of older women often get more and more brittle because they are
becoming less and less dense. Osteoporosis is the disease name for this
process, and people who suffer from it break bones more easily than normal.
For many years, women reaching menopause have been advised to
take estrogen replacement therapy (ERT) or estrogen with a progestin (called
hormone replacement therapy or HRT) to prevent this disease. But this meant
taking hormones for 20-30 years — which also has risks, including uterine
cancer (with ERT alone), blood clots, gallstones, and possibly breast
cancer.
There’s good news, though: There may be other ways to prevent,
and even treat, bone loss.
“In the past 5 or 10 years, we have recognized that
osteoporosis is a very treatable disease,” says Bruce Ettinger, MD, senior
investigator in the research division of the Kaiser Permanente Medical Care
Program in Oakland, Calif. “The old idea that you can’t treat it, you can
only prevent it, is out the window. We have new medications now that markedly
reduce women’s risk of fracture and we have other and perhaps even better
medications coming soon.”
Hormone Controversy
A June 13, 2001 Journal of the American Medical
Association (JAMA) editorial notes that the estrogen therapies
prevent postmenopausal bone loss but also that other drugs (even calcium and
vitamin D) decrease the risk of fractures independently of how dense or porous
a woman’s bones are. For that reason they are approved by the FDA not just to
prevent osteoporosis but also to treat it.
One class of drugs, the bisphosphonates — including
alendronate (Fosamax) and risedronate (Actonel) — prevents spine, hip, and
other fractures. So-called SERM (for selective estrogen receptor modulator)
drugs — including tamoxifen (Nolvadex) and raloxifene (Evista) — increase
bone density and reduce spinal fractures but not hip fractures. They may
increase the risk of blood clots and hot flashes, but some reduce breast cancer
risk.
Raloxifene is the SERM that is FDA approved for osteoporosis
therapy. Calcitonin increases bone density in the spine and reduces the risk of
spinal fractures but does not seem to reduce fractures of the hip and other
bones. When injected, it may cause an allergic reaction, urinary frequency, or
nausea in some people, though these side effects were not reported when
calcitonin was taken as a nasal spray.
Statins like Zocor (simvastatin), Mevacor (lovastatin), and
Pravachol (pravastatin) may lower the risk for hip and other fractures, may
help improvej cholesterol levels, and may reduce heart attack and stroke risk,
but are not yet FDA-approved for osteoporosis therapy.
Do Benefits Exceed Risk?
Estrogen has not been shown to significantly reduce fractures
in women who are 60 years old or over, according to the authors of the
JAMA editorial. They say, “Since women in their 50s who do not have
osteoporosis have a relatively low risk of fracture, the benefit of long-term
treatment with estrogen to prevent bone loss and fractures may not exceed the
risks.”

Canadadrugpharmacy.com: A Name you can trust-Print

admin — Mon, 08 Dec 2008 18:26:02 +0000

The urge to deliver the best Canadian drugs gives the birth of innumerable pharmacies till date. Now, as the competition is getting tougher day by day, pharmaceutical companies are trying hard to survive by keeping originality of their medicines and offering them at an affordable rate. The scenario has earned profit for public, who wish to get safe medications at a reasonable price tag. Canadadrugpharmacy.com is one of those highly apprised Canadian pharmacies who have earned kudos for delivering quality drugs at an affordable rate. The article gives an insight into the pharmacy and its several aspects. Read on.

Canadadrugpharmacy.com deals with Canadian prescription drugs. Being a leading Canadian online pharmacy, the company has witnessed profitable business for many years in a row. It is dedicated to delivering Canadian drugs at an affordable rate. The company embarked on its journey when the cost of Canada online Drugs was rising steadily. Motivated by a team of expert health practitioners, the online portal has been serving to bring simplicity in the ordering process of safe and sheltered Canadian drugs. The said Canadian online pharmacy offers great savings on all prescription drugs. Canadaphrmacymeds.com offers all popular Canada prescription drugs namely Lipitor, Celebrex, Zocor, Fosamax, Effexor, Zyrtec, Plavix, Premarin, Flomax, Paxil, Zoloft, Prevacid, and Evista to name a few.

Canadadrugpharmacy.com is again worthwhile for delivering Canada online drugs to your door within deadline. The company adheres to all possible rules and regulations pertaining to online delivery of drugs. Buying drugs from the portal is easy. You need to go to the portal, choose your drug and after reading all necessary particulars place an online order. Within a few days, this Canadian online drug store will deliver your Canadian Pharmacy medicines to your door. To bring simplicity in the ordering process, the portal gives patients a chance to place orders through online, fax, phone or mail. Therefore, a patient can bring his prescription drug without getting out of his home. Add to this, he is saving his money too by getting his drugs at an affordable rate.

To ensure the safety and effectiveness of Canada online drugs, all medicines have been inspected and approved by experts. Each prescription order must be accompanied by a valid prescription. This Canadian online pharmacy offers a flexible payment options for users. A user can made payments by Visa, MasterCard, American Express, Discover, International Money Orders, or by Personal Check (via our E-Check service). This Canada drugs online portal has round the clock customer service for all looking towards healthy solutions for a trouble free life.

Healthfacts - Media hype the new findings for Evista as an anti-breast cancer drug

admin — Fri, 05 Dec 2008 23:46:03 +0000

Initial results from a government-sponsored study indicate that the osteoporosis drug raloxifene (brand name: Evista) may protect against breast cancer. The study compared it against an older anti-breast cancer drug, tamoxifen (brand name: Nolvadex), and found both are equally good at reducing the chances of developing breast cancer. Some media reports of this study were overly enthusiastic about its finding.
The study is yet to be published. If the results hold up, Eli Lilly, maker of raloxifene, will be able to apply to the FDA for permission to promote raloxifene as a breast cancer preventive. Expect an overheated advertising campaign by Lilly touting raloxifene as a “twofor”–a drug that will save women from osteoporosis AND breast cancer.

Most Popular
10 Jobs That Pay $30 An Hour
5 Regular Mistakes In Public Speaking
3 Questions No Job Seeker Ever Wants To Be Asked?
Public Speaking: 7 Secrets Of Great Public Speakers
13 Job Interview Mistakes To Avoid

Raloxifene has been on the market since 1997. It is good at increasing bone density; completely ineffective at reducing the most serious type of fracture (hip); and minimally effective in reducing spinal fractures. Spinal fractures can cause pain and a dowager’s hump in advanced age, but many are entirely symptomless. Tamoxifen has been on the market since 1972. First as an adjunctive treatment for breast cancer and more recently (1998) as a preventive drug for healthy but high-risk women. It never took off for the latter purpose because, according to one report, many doctors were uneasy about prescribing a cancer drug to healthy women every day for five years.
Both raloxifene and tamoxifen are what is called selective estrogen receptor modulators, or SERMs, which means that they protect the breast from estrogen’s cancer-causing potential but preserve estrogen’s protective effect on the bones. This is why SERMS were initially promoted as designer estrogens.
The National Cancer Institute sponsored the new study that compared the two drugs called the STAR trial, short for Study of Tamoxifen and Raloxifene, and the initial results were posted last month on its Web site (www.cancer.gov see initial results STAR). The STAR trial included postmenopausal women at high risk for breast cancer who had been randomly assigned to take one or the other drug. The NCI hailed both drugs as having reduced the incidence of breast cancer by 50%, which was uncritically picked up by most of the media.
Here’s what the NCI should have explained: Of the 9,700-plus women in each drug group, about 165 got breast cancer. This translates to 1.7%; whereas, 3.4% would be expected to develop breast cancer had they not taken a drug. (Hence the 50% reduction in breast cancer incidence.) Another way of saying the same thing is: 98.3% of women will not get cancer if they take raloxifene or tamoxifen; whereas, if they take no drug, 96.6% of women will not get cancer. Obviously, much more research is needed to determine who is at high risk for breast cancer.
If you are thinking of taking raloxifene every day for five years, consider the following:
–It is premature to call raloxifene and tamoxifen preventive drugs. The STAR lasted only four years and breast cancer can take from 12 to 17 years to develop. Therefore, it is not known whether these drugs prevent breast cancer or merely delay its onset. The Tamoxifen Breast Cancer Prevention Trial lasted nearly five years.
–The media reports of STAR emphasized fewer adverse reactions for raloxifene. However the 29% fewer blood clots and 36% fewer uterine cancers are not considered to be statistically significant because these conditions are rare. (Findings could have occurred by chance.) However, the fewer cataracts in the raloxifene users is statistically significant.
–Raloxifene’s spinal fracture reduction benefit is small. Three-year results of a major trial showed spinal fractures in 10.1% of the women on placebos; in 6.6% of women on 60-mg/daily of raloxifene; and in 5.4% for women on 120 mg/daily of raloxifene.
–Less is known about the long-term effects of raloxifene than is known about tamoxifen. It took more than 25 years of tamoxifen use before a rare life-threatening adverse effect (endometrial sarcoma) became apparent.
COPYRIGHT 2006 Center for Medical Consumers, Inc.
COPYRIGHT 2008 Gale, Cengage Learning